2016
DOI: 10.1097/jcn.0000000000000259
|View full text |Cite
|
Sign up to set email alerts
|

The Effectiveness of Medication Adherence Interventions Among Patients With Coronary Artery Disease

Abstract: Background Despite the known benefits of medication therapy for secondary prevention of coronary artery disease (CAD), many patients do not adhere to prescribed medication regimens. Medication nonadherence is associated with poor health outcomes and higher health care cost. Objective The purpose of this meta-analysis was to determine the overall effectiveness of interventions designed to improve medication adherence (MA) among adults with CAD. Additionally, sample, study design, and intervention characterist… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
24
0
1

Year Published

2018
2018
2021
2021

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 26 publications
(27 citation statements)
references
References 51 publications
2
24
0
1
Order By: Relevance
“…The overall mean effect size of 0.300, which was calculated across 108 treatment vs. control comparisons, documents that treatment subjects had significantly better medication adherence outcomes than control subjects. This value was comparable to effect sizes reported in meta-analyses of adherence interventions conducted in general populations ( d = 0.18 to 0.37) [147, 148]; among older adults ( d = 0.33) [149]; adults with coronary artery disease ( d = 0.229) [150]; adults with heart failure ( d = 0.29) [151]; patients with adherence problems ( d = 0.301) [152]; and in targeted populations of underrepresented racial/ethnic groups ( d = 0.211) [153]. …”
Section: Discussionsupporting
confidence: 80%
See 1 more Smart Citation
“…The overall mean effect size of 0.300, which was calculated across 108 treatment vs. control comparisons, documents that treatment subjects had significantly better medication adherence outcomes than control subjects. This value was comparable to effect sizes reported in meta-analyses of adherence interventions conducted in general populations ( d = 0.18 to 0.37) [147, 148]; among older adults ( d = 0.33) [149]; adults with coronary artery disease ( d = 0.229) [150]; adults with heart failure ( d = 0.29) [151]; patients with adherence problems ( d = 0.301) [152]; and in targeted populations of underrepresented racial/ethnic groups ( d = 0.211) [153]. …”
Section: Discussionsupporting
confidence: 80%
“…The results also suggest that interventions can target multiple health behaviors without adversely affecting adherence outcomes [150]. This is important information for hypertensive populations in which other health behaviors affecting cardiovascular health such as diet and exercise must also be addressed.…”
Section: Discussionmentioning
confidence: 99%
“…Consider what might happen, on the other hand, if the meta‐review was reporting outcomes within a more focused health behavior domain, for example, cardiovascular disease (CVD) prevention and treatment. In our empirical example, when we focus on the seven meta‐analyses in the domain of CVD prevention and treatment, the CCA remains fairly minimal (ie, still less than 2%). Yet, within three of these reviews that focused on CVD, overlap was much higher (12%); they shared the same seven primary studies, and, two of these three reviews shared an additional six studies (the total unique k included across the three reviews was 98).…”
Section: Empirical Illustrationmentioning
confidence: 99%
“…Medication adherence interventions for patients with CVD have been shown to be effective when delivered by nurses, who should play an active role in designing and applying such interventions (Albert, 2008;Chase et al, 2016). A recent systematic review emphasised that cardiac rehabilitation and prevention programs should encompass a dedicated strategy for medication adherence; at present, the majority of these programs do not measure and report adherence outcomes appropriately (Santo et al, 2016).…”
Section: Discussionmentioning
confidence: 99%
“…Prescription medications, an important form of secondary prevention for CVD, have been a key factor in the 20% reduction seen in mortality rates within one year of diagnosis of acute myocardial infarction (AMI) (Chase, Bogener, Ruppar, & Conn, 2016); and the 28% reduction within three months of AMI between 2006 and (Kolandaivelu, Leiden, Gara, & Bhatt, 2014). While cardiac medications have been shown to be effective for symptom management and slowing the progression of CVD, consistent adherence to prescribed medication regimes is required to achieve these effects (Hunt et al, 2009).…”
Section: Introductionmentioning
confidence: 99%